Phase 1 dose-escalation, safety / tolerability and preliminary efficacy study of intratumoral and subcutaneous administration of GEN0101 in patients with recurrence of castration resistant prostate cancer

Trial Profile

Phase 1 dose-escalation, safety / tolerability and preliminary efficacy study of intratumoral and subcutaneous administration of GEN0101 in patients with recurrence of castration resistant prostate cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs GEN 0101 (Primary) ; GEN 0101 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Ishihara Sangyo Kaisha
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 15 Jun 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
    • 23 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top